Oncimmune Holdings plc announced that the company has signed further commercial contracts within its ImmunoINSIGHTS pharma services business. MSA and Commercial Contract Signed with Leading Global Pharmaceutical Company: Following the recent signing of a MSA with a leading global pharmaceutical company, the Company reported that it has signed a commercial contract to provide autoantibody biomarker services. A second contract has been agreed and is expected to be signed in the next few days. Both programmes are scheduled to complete and be invoiced by the end of FY2022 and the Company expects these programmes to lead to follow-on studies. Under the first contract, Oncimmune will develop a multiplexed assay to measure Immunoglobulin E (IgE) autoantibodies on its SeroTagTM platform for planned autoimmune studies. In the second, pending contract, Oncimmune will evaluate the autoantibody profiles of patient samples collected in an autoimmune trial for chronic idiopathic urticaria1 ("CIU"). This study will measure the autoimmune profile in chronic, idiopathic (meaning 'of unknown cause') cases of CIU and aims to uncover insights that will support the clinical development of a therapeutic for CIU. The company has signed an autoantibody profiling collaboration with the EORTC, an independent, non-profit cancer research organisation whose mission is to coordinate and conduct international translational and clinical research to improve the standard of cancer treatment for patients. The new research project, co-funded with the EORTC Melanoma Group and MSD, will evaluate the autoantibody profiles of patient samples collected in the ongoing phase 3 EORTC1325/KEYNOTE-054 trial investigating KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, as monotherapy for surgically resected, high-risk melanoma. The project will explore autoantibody profiles as biomarkers of clinical response in patients with melanoma recruited onto the EORTC1325/KEYNOTE-054 trial, which assessed pembrolizumab versus placebo in an adjuvant setting (in which the drug is administered after surgery). Pembrolizumab is an immune check point inhibitor ("CPI") with uses in over 15 types of cancer, including for the treatment of melanoma skin cancer, non-small cell lung cancer, bladder cancer and Hodgkin lymphoma.